Clinical trials: Empagliflozin
Liver Diseases, Hypertension, Portal
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis caused by hepatitis B, hepatitis C or nonalcoholic steatohepatitis (NASH). People can join this study if they have high blood pressure in the portal vein (main vessel going to the…
- Trial name
- NCT05282121
- Testing
- Avenciguat, Empagliflozin
- Where
- 31 sites in United States, Argentina and 14 more
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease, Acute Kidney Injury
Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.
- Conditions
- Coronary Artery Disease, Acute Kidney Injury, Contrast-Induced Acute Kidney Injury, Percutaneous Coronary Intervention
- Trial name
- FLORENCE (NCT07231939)
- Testing
- Flozin
- Where
- Poland
- Volunteers
- 4,000 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in…
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
- Trial name
- ADIPO-CKD (NCT07309094)
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor, Tirzepatide
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Cardenal Herrera University
Acute Decompensated Heart Failure
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure
Heart failure is the most common hospital admission diagnosis and shows increasing incidence and prevalence in Germany, the United States and worldwide. Improvements in the primary treatment conditions for e.g.
- Trial name
- EMPAG-HF (NCT04049045)
- Testing
- Empagliflozin 25 mg
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Christian Schulze
Acute Heart Failure, Chronic Kidney Diseases
Empagliflozin in Acute Heart Failure
The objective is to study in a prospective, interventional, single arm, cohort study the potential synergistic diuretic effect of empagliflozin, in addition to furosemide, in hypervolemic patients admitted with acutely…
- Trial name
- DRIP-AHF-1 (NCT05305495)
- Testing
- Empagliflozin 25 MG
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Heart Failure With Reduced Ejection Fraction, Heart Failure
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure
This is a multicenter, randomized, open-label pilot study to evaluate whether stepwise withdrawal of two heart failure medications-angiotensin receptor-neprilysin inhibitor (ARNI) and sodium-glucose cotransporter-2 inhibitor…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure, Ventricular Dysfunction, Left
- Trial name
- STEP-DOWN HF (NCT07631156)
- Testing
- Stepwise Withdrawal of ARNI and SGLT2i, Continued Guideline-Directed Medical Therapy
- Where
- 5 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Kyungsub Song
Diabetes Mellitus, Type 2
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus
- Trial name
- NCT02453555
- Testing
- Linagliptin, Empagliflozin + linagliptin low dose, Empagliflozin + linagliptin high dose
- Where
- 40 sites in Japan
- Volunteers
- 275 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Diabetes Mellitus
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
The investigators hypothesise that empagliflozin 10mg daily will have haemodynamic, cardiac, and renal benefits compared to placebo over 36 weeks in heart failure patients with type 2 diabetes (or pre-diabetes), leading to…
- Trial name
- SUGAR-DM-HF (NCT03485092)
- Testing
- Empagliflozin 10 MG
- Where
- United Kingdom
- Volunteers
- 105 people
- Sponsor
- NHS Greater Glasgow and Clyde
Diabetic Kidney Disease (DKD), Type 2 Diabetes
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
We are conducting this clinical trial to find out whether Guominkang-a traditional Chinese herbal formula-is safe and effective for people with diabetic kidney disease (DKD).
- Conditions
- Diabetic Kidney Disease (DKD), Type 2 Diabetes, Albuminuria
- Trial name
- NCT07907965
- Testing
- Guominkang Granules, Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing University of Chinese Medicine
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets
To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773 with repeat dosing for eight days and the exploration of the pharmacokinetics and pharmacodynamics of BI 10773 after multiple dosing…
- Trial name
- NCT01924767
- Testing
- BI 10773
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy
Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study
In patients with heart failure due to a reversible underlying cause-such as valvular heart disease or coronary artery disease-surgical or procedural correction of the underlying lesion (valve repair/replacement, TAVI, PCI, or…
- Conditions
- Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy, Heart Failure
- Trial name
- NCT07572032
- Testing
- Sacubitril / Valsartan, SGLT-2 inhibitor, SGLT2 Inhibition
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Kyungsub Song
Platelet Dysfunction Due to Drugs
The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.
The mechanistic effects of empagliflozin on platelet function profiles have not yet been ascertained.
- Trial name
- EFFECT (NCT04342819)
- Testing
- SGLT2 inhibitor
- Where
- Trinidad and Tobago
- Volunteers
- 25 people
- Sponsor
- The University of The West Indies
Diabetes Mellitus, Type 2, Acute Heart Failure
EMPA Acute Heart Failure
In this study the investigators are aiming to treat patients with acute heart failure with or without diabetes with Empagliflozin or placebo.
- Trial name
- NCT03554200
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- RWTH Aachen University
Diabetes Mellitus, Type 2
Comparative Effectiveness of Empagliflozin in the US
Empagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, was launched as a treatment for type 2 diabetes mellitus (T2DM) in the U.S. in August 2014.
- Trial name
- NCT03363464
- Testing
- Empagliflozin, DPP-4 inhibitor, GLP-1 receptor agonist
- Where
- United States
- Volunteers
- 230,000 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is a considered one of the main global health challenges; the vascular endothelium plays an important role in vascular dysfunction in DM; Hyperglycemia induced by it is recognized as the main…
- Trial name
- NCT04195243
- Testing
- Dapagliflozin Pill, Empagliflozin Pill
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- Centro Universitario de Ciencias de la Salud, Mexico
Type 2 Diabetes
Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)
Diabetes is a disorder of high blood glucose, that tends to get worse; over time, patients need more and more drugs. This pattern is caused by overwork of the body's insulin-producing β-cells, because patients' glucose levels are…
- Trial name
- CHANGE (NCT05040087)
- Testing
- Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Foundation for Atlanta Veterans Education and Research, Inc.
Erectile Dysfunction, Left Ventricular Diastolic Dysfunction
Association Between Diastolic Dysfunction and Erectile Dysfunction and the Effect of Tadalafil and SGLT2 Inhibitors on Them in Men With Metabolic Syndrome
Metabolic syndrome is associated with an increased risk of cardiovascular disease and is commonly accompanied by erectile dysfunction and subclinical cardiac dysfunction.
- Conditions
- Erectile Dysfunction, Left Ventricular Diastolic Dysfunction, Metabolic Syndrome
- Trial name
- METDDED (NCT07563647)
- Testing
- Tadalafil 5 mg, SGLT-2 inhibitor, Tadalafil plus SGLT2 inhibitors
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Kafrelsheikh University
Covid19
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
- Trial name
- ACTIV-4A (NCT04505774)
- Testing
- theraputic heparin, prophylactic heparin, P2Y12
- Where
- 101 sites in United States, Brazil and 2 more
- Volunteers
- 3,591 people
- Sponsor
- Matthew Neal MD
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg + linagliptin.
- Trial name
- NCT02489968
- Testing
- empagliflozin 10 mg + linagliptin 5 mg, empagliflozin 10 mg, empagliflozin 25 mg + linagliptin 5 mg
- Where
- 83 sites in Japan
- Volunteers
- 880 people
- Sponsor
- Boehringer Ingelheim